Notice2022-07150
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 5, 2022
Issuing agencies
Defense Department
Abstract
The DoD is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel (UF BAP) will take place.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 65 (Tuesday, April 5, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 65 (Tuesday, April 5, 2022)]
[Notices]
[Pages 19668-19669]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-07150]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Uniform Formulary Beneficiary Advisory Panel; Notice of Federal
Advisory Committee meeting
AGENCY: Under Secretary of Defense for Personnel and Readiness,
Department of Defense (DoD).
ACTION: Notice of Federal Advisory Committee meeting.
-----------------------------------------------------------------------
SUMMARY: The DoD is publishing this notice to announce that the
following Federal Advisory Committee meeting of the Uniform Formulary
Beneficiary Advisory Panel (UF BAP) will take place.
DATES: Open to the public Wednesday, April 6, 2022, 10:00 a.m.-1:00
p.m. (Eastern Standard Time).
ADDRESSES: The meeting will be held telephonically or via conference
call. The phone number for the remote access on April 6, 2022 is:
CONUS: 1-800-369-2046; OCONUS: 1-203-827-7030; PARTICIPANT CODE:
8546285.
These numbers and the dial-in instructions will also be posted on
the Uniform Formulary Beneficiary Advisory Panel Website at: <a href="https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP">https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP</a>.
FOR FURTHER INFORMATION CONTACT: Designated Federal Official (DFO)
Colonel Paul J. Hoerner, USAF, 703-681-2890 (voice), <a href="/cdn-cgi/l/email-protection#a8ccc0c986c6cbda86c2859e86c5cad086cac9d8dacdd9ddcddbdcdbe8c5c9c1c486c5c1c4"><span class="__cf_email__" data-cfemail="eb8f838ac5858899c581c6ddc5868993c5898a9b998e9a9e8e989f98ab868a8287c5868287">[email protected]</span></a> (email). Mailing address is 7700 Arlington
Boulevard, Suite 5101, Falls Church, VA 22042-5101. Website: <a href="https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP">https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP</a>. The most up-to-date changes to the meeting
agenda can be found on the website.
SUPPLEMENTARY INFORMATION: Due to circumstances beyond the control of
the DoD and the DFO, the UF BAP was unable to provide public
notification required by 41 CFR 102-3.150(a) concerning its April 6,
2022 meeting of the UF BAP. Accordingly, the Advisory Committee
Management Officer for the DoD, pursuant to 41 CFR 102-3.150(b), waives
the 15-calendar day notification requirement.
This meeting is being held under the provisions of the Federal
Advisory Committee Act (FACA) (5 U.S.C., appendix) and 41 CFR 102-3.140
and 102-3.150.
Purpose of the Meeting: The Panel will review and comment on
recommendations made to the Director, Defense Health Agency, by the
Pharmacy and Therapeutics Committee, regarding the Uniform Formulary.
Agenda
1. 10:00 a.m.-10:10 a.m. Sign In for UF BAP members
2. 10:10 a.m.-10:40 a.m. Welcome and Opening Remarks
a. Welcome, Opening Remarks, and Introduction of UF BAP Members
by Col Paul J. Hoerner, DFO, UF BAP
b. Opening Remarks by UF BAP Co-Chair Senior Chief Petty Officer
Jon R. Ostrowski, Non-Commissioned Officers Association
c. Introductory Remarks by CDR Scott Raisor, Interim Chief,
Formulary Management Branch
d. Public Written Comments by CDR Raisor
3. 10:40 a.m.-11:45 a.m. Scheduled Therapeutic Class Reviews
a. Oncological Agents: Renal Cell Carcinoma; Myelofibrosis;
Epidermal Growth Factor Receptor (EGFR) plus Non-Small Cell Lung
Cancer (NSCLC); Non-Bruton's Tyrosine Kinase Inhibitor (Non-BTKI)
for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma
(SLL); and Poly Adenosine Diphosphate-Ribose (PARP) Inhibitors
subclasses
b. Binders-Chelators-Antidotes-Overdose Agents: Hypoglycemia
Agents
4. 11:45 a.m.-12:30 p.m. Newly Approved Drugs Review
5. 12:30 p.m.-12:45 p.m. Pertinent
[[Page 19669]]
Utilization Management Issues
* Note that UF BAP discussion and vote will follow each section
6. 12:45 p.m.-1:00 p.m. Closing remarks
a. Closing Remarks by UF BAP Co-Chair Senior Chief Petty Officer
Jon R. Ostrowski
b. Closing Remarks by Col Paul J Hoerner, DFO, UF BAP
Meeting Accessibility: Pursuant to section 10(a)(1) of the FACA and
41 CFR 102-3.140 through 102-3.165, and subject to the availability of
phone lines, this meeting is open to the public. Telephone lines are
limited and available to the first 220 people dialing in. There will be
220 lines total: 200 domestic and 20 international, including leader
lines.
Written Statements: Pursuant to 41 CFR 102-3.10, and section
10(a)(3) of FACA, interested persons or organizations may submit
written statements to the UF BAP about its mission and/or the agenda to
be addressed in this public meeting. Written statements should be
submitted to the Uniform Formulary Beneficiary Advisory Panel's DFO.
The DFO's contact information can be found in the FOR FURTHER
INFORMATION CONTACT section of this notice. Written comments or
statements must be received by the UF BAP's DFO at least one (1)
calendar day prior to the meeting so they may be made available to the
UF BAP for its consideration prior to the meeting. The DFO will review
all submitted written statements and provide copies to UF BAP.
Dated: March 30, 2022.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2022-07150 Filed 4-4-22; 8:45 am]
BILLING CODE 5001-06-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 5, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.